24 research outputs found
選択的セロトニン再取り込み阻害薬とセロトニン4受容体作動薬の直腸吻合部におけるインビボ神経再建に与える効果の比較
It was recently reported that activation of enteric neural 5-HT(4) receptors (SR4) promotes reconstruction of enteric neural circuit injury in distal gut of guinea pigs and that this reconstruction involves neural stem cells. We aimed to explore a novel approach using a selective serotonin reuptake inhibitor (SSRI), which increases endogenous 5-HT, to repair enteric nerve fiber injury in the rat distal gut. Enteric nerve fiber injury was performed by rectal transection and subsequent end-to-end one-layer anastomosis. The SSRI fluvoxamine maleate (100 μmol/l) was applied locally at the anastomotic site to compare with the 5-HT(4) agonist mosapride citrate (100 μmol/l) (applied for patent) applied locally and orally. Unlike mosapride, fluvoxamine failed to promote the regeneration of the nerve fiber tract across the anastomosis. Furthermore, fluvoxamine did not generate anti-distal-less homeobox 2 (DLX2)- and anti-SR4-positive cells (neural stem cells) and/or anti-neurofilament (NF)-positive cells (neural cells) in newly formed granulation tissue at the anastomosis, whereas these cell types were observed in mosapride-treated preparations. In contrast to its effects in guinea pigs, mosapride generated 5-bromo-2'-deoxyuridine (BrdU)-positive neural cells in ganglia sites 3 mm oral and anal from the anastomosis 2 wk after nerve fiber injury. All actions of mosapride were observed after local and or oral applications. These findings indicate that local SSRI treatment does not induce in vivo nerve fiber tract growth across the anastomosis in the rat distal gut. Mosapride induces nerve fiber tract growth across the anastomosis, mediated through enteric neural stem cells possibly from neural crest-derived stem cells or mesenchymal stem cells in the bone marrow.博士(医学)・甲616号・平成26年3月17日発行元の規定により、本文の登録不可。本文は以下のURLを参照 "http://dx.doi.org/10.1152/ajpgi.00284.2011
Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer
Although hematopoietic prostaglandin D synthase (H-PGDS) is an attractive target for
treatment of a variety of diseases, including allergic diseases and Duchenne muscular
dystrophy, no H-PGDS inhibitors have yet been approved for treatment of these
diseases. Therefore, the development of novel agents having other mode of actions to
modulate the activity of H-PGDS is required. In this study, a chimeric small molecule
that degrades H-PGDS via the ubiquitin-proteasome system, PROTAC(H-PGDS)-1,
was developed. PROTAC(H-PGDS)-1 is composed of two ligands, TFC-007 (that
binds to H-PGDS) and pomalidomide (that binds to cereblon). PROTAC(H-PGDS)-1
showed potent activity in the degradation of H-PGDS protein via the
ubiquitin-proteasome system and in the suppression of prostaglandin D2 (PGD2)
production. Notably, PROTAC(H-PGDS)-1 was slightly more effective in the
suppression of PGD2 production than the known inhibitor, TFC-007. Thus, the H-PGDS
degrader—PROTAC(H-PGDS)-1—is expected to be useful in biological research and
clinical therapies
Spatial distribution of tumors in MNI standard space superimposed on a standard anatomical template.
<p>This frequency map shows the number of patients with tumor in a given voxel.</p